论文部分内容阅读
目的观察高分化甲状腺癌I型转化生长因子β(Transforming Growth Factor-β), TGF-β受体与增值细胞核抗原(proliferating cell nuclear antigen,PCNA)的表达状态,讨论TGF-β抵抗机制在甲状腺乳头状癌及滤泡状癌中的可能途径。方法取25例甲状腺乳头状癌、7例甲状腺滤泡状癌及19例正常甲状腺组织标本,免疫组化检测I型TGF-β受体和PCNA蛋白的表达水平。结果I型TGF-β受体与PCNA在甲状腺癌中的阳性率显著高于正常甲状腺组织(P<0.05),两者在甲状腺癌呈正相关关系(r=0.3637、P= 0.0437)。结论TGF-β抵抗机制在本组甲状腺癌中的实现并非通过I型TGF-β受体的丢失,而更可能是II型TGF-β受体丢失或TGF-β合成水平降低所至。
Objective To investigate the expression of TGF-β, TGF-β and PCNA in well-differentiated thyroid carcinoma and to explore the role of TGF-β in the pathogenesis of thyroid papillary thyroid Possible pathways in carcinoma and follicular carcinoma. Methods 25 cases of papillary thyroid carcinoma, 7 cases of thyroid follicular carcinoma and 19 cases of normal thyroid tissue were collected for immunohistochemistry to detect the expression of type I TGF-β receptor and PCNA protein. Results The positive rate of type I TGF-β receptor and PCNA in thyroid cancer was significantly higher than that in normal thyroid tissue (P <0.05). There was a positive correlation between them (r = 0.3637, P = 0.0437). Conclusion The mechanism of TGF-β resistance in thyroid cancer is not through the loss of type I TGF-β receptor but more likely to be loss of type II TGF-β receptor or decrease of TGF-β synthesis.